Cancer Chemotherapy and Pharmacology

, Volume 23, Supplement 1, pp S29–S32 | Cite as

Studies on the chemotherapy with 5-fluorouracil in trascatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma

  • Osaka Study Group on Hepatocellular Carcinoma
First International Symposium on Treatment of Liver Cancer Kobe, Japan, 15–16 November 1987 Session 2: Chemotherapy, Immunotherapy and Radiotherapy 5-Fluorouracil, Adriamycin, Transcatheter Arterial Chemoembolization, Hepatocellular Carcinoma

Summary

In a prospective clinical trial, 65 patients were studied in an investigation into the effects of the oral administration of 5-fluorouracil on resectable and non-resectable hepatocellular carcinoma. All patients had received initial treatment in the form of transcatheter arterial chemoembolization with adriamycin. No significant effect on the survival periods was demonstrated either in patients with resectable carcinoma or in those with non-resectable carcinoma, even though the survival rates were too high to reach an accurate conclusion (the lowest survival rate was 80%, 12/15, obtained in non-resectable carcinoma patients without 5-fluorouracil administration). 5-Fluorouracil administration did not significantly prolong the interval before recurrence in patients with resectable carcinoma (P=0.139). However, its favorable effect on the interval up to disease progression was noted in patients with non-resectable carcinoma when a log-rank test was used to carry out a statistical analysis (P=0.049), though it was not demonstrated by the Wilcoxon test (P=0.102). Thus, adjuvant chemotherapy with 5-fluorouracil seems to have potential in the palliative effects of transcatheter arterial chemoembolization on non-resectable hepatocellular carcinoma, but further studies are necessary before a final conclusion can be reached.

Keywords

Carcinoma Hepatocellular Carcinoma Adjuvant Chemotherapy Final Conclusion Wilcoxon Test 

References

  1. 1.
    Al-Idrissi HY, Ibrahim EM, Abdel Satir A, Satti MB, Al-Kasem S, Al-Qurain A (1985) Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotheraphy using 5-fluorouracil, adriamycin and mitomycin-C. Hepato-gastroenterology 32: 8Google Scholar
  2. 2.
    Bonadonna G, Valagussa P (1987) Current status of adjuvant chemotheraphy for breast cancer. Semin Oncol 14: 8Google Scholar
  3. 3.
    Chlebowski RT, Chan KK, Tong MJ, Weiner JM, Ryden VMJ, Bateman JR (1981) Adriamycin and methyl-CCNU combination theraphy in hepatocellular carcinoma: Clinical and pharmaco-kinetic aspects. Cancer 48: 1088Google Scholar
  4. 4.
    Choi TK, Lee NW, Wong J (1984) Chemotheraphy for advanced hepatocellular carcinoma: adriamycin versus quadruple chemotheraphy. Cancer 53: 401Google Scholar
  5. 5.
    Falkson G, Moertel CG, Lavin P, Pretorius FJ, Carbone PP (1978) Chemotheraphy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 42: 2149Google Scholar
  6. 6.
    Falkson G, Macintyre JM, Moertel CG, Johnson LA, Scherman RC (1984) Primary liver cancer: an eastern cooperative oncology group trial. Cancer 54: 970Google Scholar
  7. 7.
    Gastrointestinal Tumor Study Group (1985) Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 312: 1465Google Scholar
  8. 8.
    Goldstein HM, Wallace S, Anderson JH, Bree RL, Giantarco C (1976) Transcatheter occlusion of abdominal tumors. Radiology 120: 539Google Scholar
  9. 9.
    Liver Cancer Study Group of Japan (1983) The general rules for the clinical and pathological study of primary liver cancer. Kimbara shuppan, Tokyo (in Japanese)Google Scholar
  10. 10.
    Melia WM, Johnson PJ, Williams R (1983) Induction of remission in hepatocellular carcinoma: a comparison of VP 16 with adriamycin. Cancer 51: 206Google Scholar
  11. 11.
    Ohishi H, Uchida H, Yoshimura H, Ohue S, Ueda J, Katsuragi M, Matsuo N, Hosogi Y (1985) Hepatocellular carcinoma detected by iodized oil: use of anticancer agents. Radiology 154: 25Google Scholar
  12. 12.
    Okamura J, Horikawa S, Fujiyama T, Monden M, Kambayashi J, Sikujara O, Sakurai M, Kuroda C, Nakamura H, Kosaki G (1982) An appraisal of transcatheter arterial embolization combined with transcatheter arterial infusion of chemotherapeutic agent for hepatic malignancies. World J Surg 6: 352Google Scholar
  13. 13.
    Paumgartner G, Probst P, Kraines R, Leevy CM (1970) Kinetics of indocyanine green removal from the blood. Ann N Y Acad Sci 170: 134Google Scholar
  14. 14.
    Sakurai M, Okamura J, Kuroda C (1984) Transcatheter chemoembolization effective for treating hepatocellular carcinoma: a histopathologic study. Cancer 54: 387Google Scholar
  15. 15.
    Schein PS (1985) The role of chemotheraphy in the management of gastric and pancreatic carcinomas. Semin Oncol 12: 49Google Scholar
  16. 16.
    Ukikusa M, Shimahara Y, Ozawa K, Shimahara Y, Asano M, Nakatani T, Tobe T (1981) Biological significance of changes in blood ketone body ratio after major hepatic resection. Arch Surg 116: 781Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • Osaka Study Group on Hepatocellular Carcinoma

There are no affiliations available

Personalised recommendations